The DMBX1 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population designed for functional interrogation of the DMBX1 transcription factor. As a heterogeneous cell pool, this product carries a diverse array of target-gene disruptions, making it an ideal resource for pooled screening approaches and high-throughput phenotypic analyses. Unlike clonal lines, the polyclonal format preserves genetic diversity, reducing the risk of clonal artifacts while maintaining robust knockout representation for unbiased loss-of-function studies.
The host HAP1 cell line is a near-haploid human male chronic myeloid leukemia-derived line, originally generated from the KBM-7 isolate. Its haploid karyotype simplifies genetic analysis, as a single disruptive event suffices to produce a full knockout phenotype, making it exceptionally useful for CRISPR-based functional genomics and genetic interaction screens. HAP1 cells exhibit stable growth and are widely utilized for essential gene identification, drug sensitivity profiling, and systematic mapping of signaling networks in a minimal genetic background.
DMBX1 encodes a paired-like homeodomain transcription factor that functions as a transcriptional repressor during embryonic development, particularly in the brain and eye. Its activity is modulated by SHH and WNT3A morphogens, which signal through PTCH1/GLI1 and CTNNB1, respectively. DMBX1 is under direct transcriptional control of PAX6 and OTX2, and it physically interacts with PAX6 and TLE/HDAC1 co-repressor complexes. It directly represses target genes such as CRYAA, CRYBB2, SIX3, and NEUROD1, thereby tuning progenitor cell proliferation and differentiation.
In the HAP1 near-haploid context, the polyclonal DMBX1 knockout pool enables highly sensitive genetic perturbation screens to uncover synthetic lethal partners, identify modulators of DMBX1-mediated repression, and dissect downstream signaling effectors. Although HAP1 is a leukemia-derived line, the DMBX1 pathway components are broadly conserved, so this system can be paired with differentiation or co-culture methods to explore retinal and neural developmental programs. The haploid background maximizes screening efficiency, facilitating genome-wide CRISPR screens to identify DMBX1-interacting pathways.
Researchers can apply the DMBX1 knockout cells in a range of assays: CRISPR haploid screens for genetic interaction mapping, RNA-seq for transcriptome profiling, RT-qPCR and Western blotting for target validation, co-immunoprecipitation for protein complex analysis, immunofluorescence for subcellular localization, and flow cytometry or proliferation assays for phenotypic characterization. Key applications include high myopia disease modeling, anterior segment dysgenesis research, and drug target identification along the SHH-WNT-PAX6 axis. For more information, please contact Ascent Research.
